In metachromatic leukodystrophy (MLD), the deficiency of the lysosomal enzyme arylsulfatase A (ARSA) leads to demyelination in the central and peripheral nervous system and ultimately to death. Allogeneic hematopoietic SCT (HSCT) is currently the only treatment for adult and late-onset juvenile MLD, although it is still in question because of insufficient follow-up. We wanted to determine whether HSCT could halt the progression of adult and late-onset juvenile MLD. Four treated unrelated patients and three untreated siblings were included in the study, and followed regularly for up to 18 years after transplantation. The patients were assessed from clinical examination, ARSA enzyme levels, magnetic resonance imaging of the brain and neuropsychological and neurophysiological tests. In the treated patients, ARSA levels were normal up to 18 years after transplantation. The parameters evaluated stabilized and remained stable after a latency period of 12-24 months. Two patients live normal lives, partially in a protected environment. The other two patients stabilized at a low cognitive and functional level. One of the controls is demented, one is in a vegetative state and one died. We conclude that, in comparison with their untreated siblings, HSCT halted the progression of the disease in our treated patients.
INTRODUCTION
In the autosomal recessively inherited disorder metachromatic leukodystrophy (MLD), deficiency in the lysosomal enzyme arylsulfatase A (ARSA) causes an accumulation of sulfatide, which leads to central and peripheral demyelination, and ultimately to death. MLD is divided into different subgroups according to the patient's age at onset of the initial symptoms: late-infantile (0.5-2 years), early-juvenile (2-6 years), late-juvenile (6-16 years) and adult (⩾16 years). In adult and late-juvenile MLD with onset at >12 years of age, psychiatric symptoms with personality and intellectual changes, and poor school or job performance precedes further mental deterioration and impairment of memory functions. 1, 2 Depression, hypomania or psychosis is common, and in adult MLD, the disease may present as a schizophrenic disorder. 3 The disease has a variable, often slow but progressive course with a mean survival of 12 years after onset of the initial symptoms. 4 After treatment with allogeneic hematopoietic SCT (HSCT), transplanted macrophages migrate through the blood-brain barrier and then differentiate into microglia, which replace ARSA-deficient microglia 5 and also support them with functional ARSA through cross-correction of the enzyme. 1 HSCT is currently the only treatment in clinical use for late-juvenile and adult MLD, but the long-term results that have been published are few and inconclusive. [6] [7] [8] [9] [10] [11] [12] [13] 
PATIENTS AND METHODS

Study design and patients
In this observational study, we wanted to determine whether HSCT was able to halt the progression of adult and late-onset juvenile MLD.
The study population consisted of the four unrelated patients with latejuvenile MLD or adult MLD who underwent treatment with HSCT at the Karolinska University Hospital until 2012. One of the patients (patient A) has been described previously. 12 Three patients (patients A-C) had one sibling each with MLD (controls A-C) who served as case-controls. The siblings were not transplanted because of diagnosis was too late (controls A and C) or non-existing treatment in 1975 (control B). The patients were examined with magnetic resonance imaging of the brain, neurophysiological tests, neuropsychological tests and leucocyte-ARSA levels before transplantation and~0.5, 1, 2, 4, 6, 8, 10 and 18 years after transplantation. The four patients had different lengths of follow-up, depending on how much time had passed since their HSCT. For the controls, less extensive follow-up data were available. They had a longer follow-up than their siblings, as in all three cases they were the first to be affected by the disease. Also, all three controls had an earlier onset of symptoms than that of their treated sibling. However, once there were neurological or psychiatric symptoms, all sibling pairs had an equivalent progression of the disease. All participants had the same level of health insurance and the participants' regular health staff was responsible for all medical care. No additional medical care was given to any of the participants through their participation in the study, apart from the increased care during the months following HSCT for the patients. The study was performed within the Swedish national health care insurance, hence neither the investigations nor the interpretations of the results were blinded. No author received compensation of any kind for their work with the study. Details of the study participants are given in Table 1 .
Standard protocol approvals and patient consents
The study design was approved by the regional ethical review board at the Karolinska Institute. Written informed consent was obtained from all participants (or guardians of participants) participating in the study (consent for research).
Primary research question
Is HSCT able to halt the disease progression of adult and late-onset juvenile MLD?
Transplantation
Details of the patients and donors transplantation procedures are given in Table 1 . The donors were an HLA-identical sibling in patient A and unrelated in the other three cases. The sibling donor for patient A had normal values of ARSA in the peripheral blood. HLA typing was genomic for classes I and II.
14 Conditioning was BU p.o. 4 mg/kg/day for four days and CY 50 mg/kg for four days in two patients and CY combined with 10 Gy of total body irradiation in one. The fourth patient was given fludarabine 30 mg/m2 for 6 days and treosulfan 12 mg/kg for 3 days. 15 Patients A-C were treated with thymoglobulin 8 mg/kg (Genzyme, Cambridge, MA, USA) and patient D was given alemzumab (Genzyme). Immunosuppression was cyclosporine and four doses of MTX. 16 Supportive care has been reported in detail previously. 17 
Neurophysiological tests
Three neurophysiological tests were used to assess central demyelination: electroencephalography (EEG), visual evoked potential and somatosensory evoked potential with stimulation of the median and tibial nerves and recording of the response from the sensory cortex. To make the EEG results more comprehensible to the reader, a senior specialist in neurophysiology graded the results from 0 to 3, where 0 is normal, 1 is slightly pathological, 2 is pathological and 3 is severely pathological.
Peripheral nerve conduction was assessed with electroneurography of the median, radial, peroneal, tibial and sural nerves. The results were also reported as an index (electroneurography-Ix), based on 12 electrophysiological parameters, and expressed as the mean deviation from age-and height-adjusted normal values in s.d. The use of the index enables detection of slight impairments in nerve conduction and in progression of polyneuropathy over time. 18 
Neuroradiology
All patients underwent neuroradiological imaging with magnetic resonance imaging of the brain before and following transplantation, to follow demyelination and cerebral atrophy. We used the scoring system for magnetic resonance imaging observations in MLD presented by Eichler et al. 19 In this system, white matter in different areas of the brain is categorized as either normal (0 points), faint hyperintensive (1 point) or dense hypertensive (2 points). This results in a score of between 0 and 34 points, where 0-6 points indicate mild disease, 7-15 points indicate moderate disease and 16-34 points indicate severe disease.
Neuropsychology
Cognitive impairment was assessed with the Wechsler Adult Intelligence Scale (WAIS) Revised and WAIS-III. WAIS-III is a developed version of WAIS Revised, and the standardization of the tests enables direct comparison of the results. Verbal intelligence quotient (IQ), performance IQ and full-scale IQ were estimated from the different WAIS subtests used. Practice effects regarding the different tests are not thought to be strong enough to influence the results, and when dementia is present, no practice effect is detectable. 20 Generally, patients with MLD tend to have higher scores for Verbal IQ than for performance IQ. 9, 11, 12 The same reference values for IQ in the WAIS tests were kept over time irrespective of the ageing of the patients, to give a representative view of the patients' development over time.
Biochemical assays and DNA analysis ARSA levels in leukocytes were measured with standard methods before and after transplantation. DNA was analyzed using standard methods.
RESULTS
Patient A
Patient A, a female born in 1964, started university studies and at 24 years of age she gave birth to twins. Then her parents noted gradual onset of personality changes and increasing difficulties in activities of daily living (ADL) and in her ability to care for her children. She entered a depressive state followed by a schizophreniform one, and was referred to a psychiatric clinic. The patient had loss of impulse control, disinhibitory behavior, attention problems and difficulties in spatiotemporal orientation and planning. She was diagnosed with adult MLD 4 years after the initial symptoms and was transplanted with BM from her HLAidentical sister 10 weeks after diagnosis. She was discharged 22 days after transplantation, after an uneventful course of events. There was a slow but steady improvement. Now, 18 years post transplantation, she lives independently in a stable relationship Abbreviations: ATG = anti thymocyte globulin; Flu = fludarabine; NA = not applicable; NC = nucleated cell; PLT = platelet; Treo = treosulfan; URD = unrelated donor.
Hematopoietic SCT for late MLD M Solders et al and works regular hours in a protected environment. She still requires help to remember the order in which to perform different tasks. Patient C Patient C is a female born in 1983. At 16 years of age, she started to experience hand tremor, clumsiness, and weakness in the lower extremities. The symptoms progressed to gait, balance, coordination, and cognitive impairment with difficulties in concentration, writing and reading. At 17 years of age, she became depressed, followed by a period of euphoria and social disinhibition. Before the transplantation, she had walking difficulties, and her hand tremor had worsened. She was diagnosed with MLD 18 months after her initial symptoms, and she received a BMT from an unrelated HLA-matched donor 18 months after diagnosis. During the first three years after transplantation, she had chronic GVHD of the liver which then gradually improved. Seven years post transplantation, her initiative, talking, vocabulary, and memory-including distant memory-improved. At follow-up 10 years after transplantation, she lives in an apartment in a nursing home. She is partly wheelchair-dependent and is able to walk short distances with assistance. She can eat with a spoon but otherwise she requires assistance for ADL. She is socially adequate, speaks four languages, and sings in a choir.
Patient D Patient D is a female born in 1988. At 18 years of age, her parents and high-school teachers began to notice problems with concentration and memory. Initially, she was diagnosed with depression and medicated with an SSRI, without effect. One year after her first symptoms, her cognitive impairment had begun to influence her ADL including getting lost while taking the bus, as well as counting, conversation and vocabulary deficits. Apraxia, urinary incontinence and peripheral numbness followed, and despite these symptoms, she seemed unaware of her rapid deterioration. She was diagnosed with MLD 18 months after the first symptoms and was transplanted 12 weeks later with BM from an HLA-mismatched unrelated donor. After graft rejection 2 months post transplantation, two new infusions of donor T cells resulted in conversion to full donor chimerism. At follow-up 4 years after transplantation, she lives in her own apartment with 24-hour assistance, and like patient A is limited mainly regarding organization of ADLs. She works part-time in a bakery. Relatives describe a steady improvement in cognitive functions since the transplantation, and she is able to discuss the treatment and its effects.
Control A Control A is the older brother of patient A, and he was born in 1961. At 18 years of age, he became psychotic and was admitted to a psychiatric hospital. At 30 years of age, he began to have epileptic seizures and this, in combination with his sister's MLD diagnosis, led to his diagnosis. Since then, he has progressively deteriorated. At follow-up at the age of 50 years, he has dysphagia and fecal and urinary incontinence. He can barely communicate with more than one word at a time and is beginning to have problems in recognizing everyday utensils, for example, a fork.
Control B Control B was the older sister of patient B, and she was born in 1962. At age of 13 years, she developed gait and balance disturbances that were soon followed by problems in coordination and speech. She quickly deteriorated and was wheelchair-bound at the age of 14 years. When she turned 17 years old, she could not manage any ADL and was fed through a nasogastric tube. Her last 17 years were spent in a nursing home, where she died at 34 years of age.
Control C Control C is the older sister of patient C, and she was born in 1975. At the age of 9 years she had gait and balance disturbances, followed by deterioration in school performance. Three years after the initial symptoms, she was diagnosed with MLD, and shortly after this she became wheelchair-bound. She gradually developed deficits in concentration and vocabulary, and she had difficulty in following a conversation. At follow-up (at 36 years of age), she is in a nursing home. She is blind and unresponsive, but sometimes reacts with movements to sounds and tactile stimuli.
Enzyme levels and chimerism Details on engraftment are given in Table 1 . Chimerism was not analyzed at the time patient A was transplanted. Patients C and D had developed full donor chimerism. Patient B had initially developed full donor chimerism, but became mixed 2 months after transplantation where he stabilized. Post transplantation, all patients had normal peripheral blood values. All four patients had normal ARSA levels in peripheral blood (8.8-19 μkat/kg) within 1 month of transplantation.
Summary of results
The results of repeated follow-up (4, 10, 12 and 18 years after transplantation) are given in Table 2 . For the untreated controls, the time of follow-up reflects the number of years they have been receiving somatic care for their symptoms of MLD. EEGs from all four patients showed no further deterioration after the examination at 12 months post transplantation. The EEGs for control A have shown no change from the initial severe pathology. The EEGs for control B, however, became more and more pathological until her death. Visual evoked potentials were stable for all four patients (±20 ms). The visual evoked potentials for control B deteriorated until her death (−55 ms). The somatosensory evoked potentials for all four patients were all stable over time (±3 ms). As shown in Figure 1 , the electroneurographs from the HSCT patients improved (A and D) or were stable (B and C). The electroneurographs from controls A and B deteriorated. The score calculated from the magnetic resonance imaging from patients A-D and control A all showed severe disease, but all the transplanted patients had stabilized 6-12 months after transplantation, as shown in Figure 2 . Neuropsychological tests from patients A, C and D all showed a low but stable full-scale IQ level, as shown in Figure 3 , with a discrepancy between verbal IQ (higher) and performance IQ (lower). Clinical assessment (detailed anamnesis including ADL and social functions, and neurological status) showed a slight improvement in functional status for patients A, C and D and a stable functional status for patient B. Functional status deteriorated for controls A and C. Control B had a progressive disease and died from the MLD.
DISCUSSION
Reports on HSCT as a treatment for adult and late-onset juvenile MLD have raised doubts concerning the ability to distinguish halted progression from very slow disease progression. 6, 7, 13, 21 Also, the fact that HSCT is not standardized at different centers prevents us from finding a definitive answer to the question of whether HSCT is a safe and effective treatment for adult and lateonset juvenile MLD. For example, regionalization and specialization has been shown to reduce TRM as well as acute and chronic GVHD. In order to address this crucial question, we included three sibling case-control pairs in our study, all diagnosed with MLD. Thus, we were able to compare progression of the untreated disease with that in a sibling with the same mutations who had undergone HSCT. The results show convincingly that HSCT can halt the progression of adult and late-onset juvenile MLD. This is further supported by the discouraging outcome in the affected sibling controls. In 1989, Clarke et al. reported two siblings with MLD where one had a much later onset of symptoms as well as a much slower disease progression. 24 In our material, the age of onset was earlier for all three untreated controls, but the disease progression was then equivalent between the sibling pairs. Also, we judge it is more likely that the difference between case controls described in this paper is due to the intervention, rather than because all three pairs happened to have a similar rare intrafamilial variability.
22,23
Ideally, the controls should have undergone the same extensive follow-up as did the treated patients. However, as the expenses were to be covered by the general health care insurance, this could not be done.
Apart from survival as an end point, it is important to evaluate the quality of life of the treated patients. It is unfortunate that an objective instrument to measure quality of life was not included in this study. However, when talking to the patients and their family members who have experienced the devastating effects of the disease first hand, no one regrets undergoing the treatment. All treated patients are independently living their lives on their own conditions, although all require various adaptations of their environments and aid from society.
Our patients had a more rapid progression of MLD during the transplantation period, an observation also reported by de Hosson et al. 11 Deterioration of the parameters investigated slowed and ultimately stopped, then remaining stable for as long as 18 years after transplantation (as in patient A). The time between the transplantation and the arrest of progression was individual, but it was within 12-24 months, an observation that concurs with other published material. 9, 25, 26 One of our patients developed mixed chimerism, but the available donor-derived cells provided enough enzyme to normalize the peripheral levels of ARSA. This finding is concurrent with the experience of HSCT for Gaucher's disease, where a stable mixed chimerism is sufficient for an excellent clinical outcome. 27 The three siblings who had not undergone HSCT all steadily deteriorated. Control A is wheelchair-bound, is totally incontinent and has lost most of his ability to speak. Control B died from the MLD. Control C is totally unresponsive, living in a vegetative state. Table 2 .
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